Variable | Non-elderly (age <65 years) (n=85) | Elderly (age ≥65 years) (n=42) | P value |
Age | 55.7±8.3 | 72.0±5.4 | |
Race | |||
White | 76 (89.4) | 39 (92.9) | 0.39 |
Black | 4 (4.7) | 3 (7.1) | |
Other | 5 (5.9) | 0 (0.0) | |
BMI | 28.9±7.6 | 26.5±6.3 | 0.08 |
ASA score at surgery | |||
0–2 | 21 (24.7) | 9 (21.4) | 0.76 |
3–4 | 64 (75.3) | 33 (78.6) | |
Medical comorbidities | |||
HTN | 30 (35.3) | 26 (61.9) | 0.004 |
DM | 3 (3.5) | 8 (19.0) | 0.006 |
VTE | 13 (15.3) | 4 (9.5) | 0.37 |
CAD | 4 (4.7) | 5 (11.9) | 0.16 |
CKD | 5 (5.9) | 2 (4.8) | 0.99 |
Pulmonary disease | 11 (12.9) | 5 (11.9) | 0.87 |
Genetic cancer syndrome | |||
BRCA1 | 4 (4.7) | 4 (9.5) | 0.28 |
BRCA2 | 5 (5.9) | 1 (2.4) | |
None | 42 (49.4) | 25 (59.5) | |
Unknown | 34 (40.0) | 12 (28.6) | |
Histology | |||
Serous | 68 (80.0) | 40 (95.2) | 0.42 |
Endometrioid | 2 (2.4) | 1 (2.4) | |
Clear cell | 5 (5.9) | 0 (0.0) | |
Carcinosarcoma | 1 (1.2) | 0 (0.0) | |
Mucinous | 4 (4.7) | 1 (2.4) | |
Other | 5 (5.9) | 0 (0.0) | |
Indication for HIPEC | |||
Interval CRS | 45 (52.9) | 31 (73.8) | 0.024 |
Recurrent CRS | 40 (47.1) | 11 (26.2) | |
Preoperative hematocrit (mg/dL) | 33.5 (31.7, 36.0) | 33.8 (29.8, 36.4) | 0.49 |
CA125 prior to HIPEC | 37.0 (20.0, 103.0) | 28.1 (15.0, 165.0) | 0.56 |
Cycles of NACT | 4.0 (3.0, 4.0) | 3.0 (3.0, 4.5) | 0.98 |
NACT regimen for interval | |||
CRS patients | 18 (40.0) | 5 (16.1) | 0.23 |
Carboplatin AUC 6 paclitaxel 175 mg/m2 q21 | 11 (24.4) | 8 (25.8) | |
Carboplatin AUC 6 q21d paclitaxel 80 D1,8,15 | 0 (0.0) | 2 (6.5) | |
Carboplatin AUC 6 q21 paclitaxel 60 D1, 8, 15 | 10 (22.2) | 9 (29.0) | |
Carboplatin AUC 5 paclitaxel 135 mg/m2 q21 | 3 (6.7) | 3 (9.7) | |
Carboplatin AUC 5 q21d paclitaxel 80 D1,8,15 | 2 (4.4) | 3 (9.7) | |
Carboplatin AUC 5 q21 paclitaxel 60 D1, 8, 15 | 1 (2.2) | 10 (32.3) | |
Other |
Categorical variables are presented as n (%); continuous variables are presented as mean with SD or median with interquartile range (25, 75).
ASA, American Society of Anesthesiologists; AUC, area under the curve; BMI, body mass index (kg/m2); CA125, cancer antigen 125; CAD, coronary artery disease; CKD, chronic kidney disease; CRS, cytoreductive surgery; DM, diabetes mellitus; HIPEC, hyperthermic intraperitoneal chemotherapy; HTN, hypertension; NACT, neoadjuvant chemotherapy; q21d, every 21 days; VTE, venous thromboembolic disease.